Design, Synthesis, and Biological Evaluation of Proteolysis-Targeting Chimeras as Highly Selective and Efficient Degraders of Extracellular Signal-Regulated Kinase 5

被引:4
|
作者
Pan, Pengming [1 ]
Geng, Tongtong [1 ]
Li, Zhongtang [1 ]
Ding, Xuyang [1 ]
Shi, Mengyuan [2 ]
Li, Yang [3 ]
Wang, Yashuai [1 ]
Shi, Yuanyuan [1 ]
Wu, Jiaojiao [1 ]
Zhong, Liang [1 ]
Ji, Dengbo [2 ]
Li, Zhongjun [1 ]
Meng, Xiangbao [1 ]
机构
[1] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
[2] Peking Univ Canc Hosp & Inst, Minist Educ, Dept Gastrointestinal Surg 3, Key Lab Carcinogenesis & Translat Res, Beijing 100142, Peoples R China
[3] Tianjin Univ Sci & Technol, Coll Biotechnol, China Int Sci & Technol Cooperat Base Food Nutr S, Tianjin 300457, Peoples R China
基金
中国国家自然科学基金;
关键词
ACTIVATED PROTEIN-KINASE; ERK5; INHIBITOR; GROWTH; PHOSPHORYLATION; MELANOMA; ERK1/2; SUPPRESSION; RESISTANCE; LEUCINE;
D O I
10.1021/acs.jmedchem.3c00864
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Extracellular signal-regulated kinase 5 (ERK5) is recognized as a key member of the mitogen-activated protein kinase family and is involved in tumor growth, migration, and angiogenesis. However, the results of ERK5 inhibition in multiple studies are controversial, and a highly specific ERK5-targeting agent is required to confirm physiological functions. Using proteolysis-targeting chimera technology, we designed the selective ERK5 degrader PPM-3 and examined its biological effect on cancer cells. Interestingly, the selective degradation of ERK5 with PPM-3 did not influence tumor cell growth directly. Based on proteomics analysis, the ERK5 deletion may be associated with tumor immunity. PPM-3 influences tumor development by affecting the differentiation of macrophages. Therefore, PPM-3 is an effective small-molecule tool for studying ERK5 and a promising immunotherapy drug candidate.
引用
收藏
页码:13568 / 13586
页数:19
相关论文
共 23 条
  • [21] Scaffold oriented synthesis part 4: Design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions
    Akritopoulou-Zanze, Irini
    Wakefield, Brian D.
    Gasiecki, Alan
    Kalvin, Douglas
    Johnson, Eric F.
    Kovar, Peter
    Djuric, Stevan W.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (05) : 1480 - 1483
  • [22] Scaffold oriented synthesis. Part 3: Design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing [2+3] cycloadditions
    Akritopoulou-Zanze, Irini
    Wakefield, Brian D.
    Gasiecki, Alan
    Kalvin, Douglas
    Johnson, Eric F.
    Kovar, Peter
    Djuric, Stevan W.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (05) : 1476 - 1479
  • [23] Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives
    Okaniwa, Masanori
    Hirose, Masaaki
    Arita, Takeo
    Yabuki, Masato
    Nakamura, Akito
    Takagi, Terufumi
    Kawamoto, Tomohiro
    Uchiyama, Noriko
    Sumita, Akihiko
    Tsutsumi, Shunichirou
    Tottori, Tsuneaki
    Inui, Yoshitaka
    Sang, Bi-Ching
    Yano, Jason
    Aertgeerts, Kathleen
    Yoshida, Sei
    Ishikawa, Tomoyasu
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (16) : 6478 - 6494